Newsletter | April 9, 2026

04.09.26 -- New Editing Modalities Driving Scalable Genomic Medicine

A Faster Path To Genomic Medicine Feasibility

Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

 

In Vivo RNA Tuning For Liver Gene Editing Efficiency

Optimizing mRNA-based therapeutics requires more than just selecting a target. Explore how internal mRNA modifications, codon and UTR optimization, and guide RNA tuning can significantly enhance editing potency in vivo, even at low doses.

 

Building A Unique Portfolio Of Therapeutic Base Editors

Stepwise engineering produces adenine base editors (ABEs) with tunable potency, precision, PAM range, and context specificity, enabling robust and targeted genome editing across diverse therapeutic sites.

 

SOLUTIONS

LEG14-Mediated TCR Knock-In For T-Cell Engineering

LEG14 nuclease and mbDNA templates enable efficient, non-viral TCR knock-in in T-cells, doubling NYESO-1 targeting efficiency compared to plasmid-based approaches.

• Request Information

 

 

 

Opening New Frontiers In Genomic Medicine

This platform's integrated capabilities span editor discovery, protein engineering, off-target analysis, and delivery systems such as LNP and AAV, streamlining the path from concept to clinic.

• Request Information